These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34053011)

  • 1. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.
    Glaspy JA; Wolf M; Strauss WE
    Adv Ther; 2021 Jul; 38(7):3531-3549. PubMed ID: 34053011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypophosphatemia following the administration of intravenous iron formulations: A case report and literature review].
    Lecoq AL; Dong C; Carbonnel F; Becquemont L
    Therapie; 2021; 76(6):705-714. PubMed ID: 33962799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    World J Gastroenterol; 2021 May; 27(17):2039-2053. PubMed ID: 34007138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer formulations of intravenous iron: a review of their chemistry and key safety aspects - hypersensitivity, hypophosphatemia, and cardiovascular safety.
    Blumenstein I; Shanbhag S; Langguth P; Kalra PA; Zoller H; Lim W
    Expert Opin Drug Saf; 2021 Jul; 20(7):757-769. PubMed ID: 33993818
    [No Abstract]   [Full Text] [Related]  

  • 8. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review.
    Glaspy JA; Lim-Watson MZ; Libre MA; Karkare SS; Hadker N; Bajic-Lucas A; Strauss WE; Dahl NV
    Ther Clin Risk Manag; 2020; 16():245-259. PubMed ID: 32308402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management.
    Schaefer B; Tobiasch M; Wagner S; Glodny B; Tilg H; Wolf M; Zoller H
    Bone; 2022 Jan; 154():116202. PubMed ID: 34534708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Risk of Hypophosphatemia Following the Administration of Intravenous Iron Formulations: A Network Meta-Analysis.
    Bellos I; Frountzas M; Pergialiotis V
    Transfus Med Rev; 2020 Jul; 34(3):188-194. PubMed ID: 32819760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
    Schaefer B; Tobiasch M; Viveiros A; Tilg H; Kennedy NA; Wolf M; Zoller H
    Br J Clin Pharmacol; 2021 May; 87(5):2256-2273. PubMed ID: 33188534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.
    Vilaca T; Velmurugan N; Smith C; Abrahamsen B; Eastell R
    J Bone Miner Res; 2022 Jun; 37(6):1188-1199. PubMed ID: 35426179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteomalacia following intravenous iron suppletion].
    Koks N; Donga E; Appelman-Dijkstra NM
    Ned Tijdschr Geneeskd; 2021 Oct; 165():. PubMed ID: 34854600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
    Dashwood A; Vale C; Laher S; Chui F; Hay K; Wong YW
    J Clin Pharmacol; 2021 Apr; 61(4):515-521. PubMed ID: 33051909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial.
    Zoller H; Wolf M; Blumenstein I; Primas C; Lindgren S; Thomsen LL; Reinisch W; Iqbal T
    Gut; 2023 Apr; 72(4):644-653. PubMed ID: 36343979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ferric carboxymaltose on markers of mineral and bone metabolism: A single-center prospective observational study of women with iron deficiency.
    Frazier R; Hodakowski A; Cai X; Lee J; Zakarija A; Stein B; David V; Wolf M; Isakova T; Mehta R
    Bone; 2020 Dec; 141():115559. PubMed ID: 32730929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.
    Adkinson NF; Strauss WE; Macdougall IC; Bernard KE; Auerbach M; Kaper RF; Chertow GM; Krop JS
    Am J Hematol; 2018 May; 93(5):683-690. PubMed ID: 29417614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.